AVALIAÇÃO DA EFICÁCIA E SEGURANÇA NO USO DA CITARABINA PARA MOBILIZAÇÃO DE CÉLULAS TRONCO HEMATOPOIÉTICAS EM UM HOSPITAL DE REFERÊNCIA DO NORDESTE

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) is largely used in the treatment of patients with hematological malignancies. As these cells circulate in small amounts in the periphery, the use of regimens that promote their mobilization is essential. In this study, we retrospectively analyzed the efficiency and safety of mobilization based on intermediate-dose Ara-C (1,6 g/m²) + Filgrastrin ( 10 mcg/kg/dia) in 157 patients treated by the Sistema Único de Saúde at the Hematology and Bone Marrow Transplantation Service of the Real Português de Beneficência Hospital, in Recife – PE. The sample included patients with the diagnosis of Multiple Myeloma (58,6%), Lymphomas (29,9%) and other malignancies (11,5%). The target yield of 2,0 x 10 6 CD34+ cells/Kg was achieved by 148 patients (94,3%), in most cases (84,1%) in a single apheresis, and the median number of CD34+ cells collect was 9,5 x 10 6 cells/Kg. No patient mobilized experienced febrile neutropenia, however, 79 patients (50,3%) required platelet transfusion. The median days of neutrophil recovery was 11 days. In view of this results, we suggest that the use of intermediate-dose Ara-C + Filgrastim is safe and effective as a mobilization protocol.